Does Cigna cover Wegovy?

Yes. Cigna covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.

How long does a Wegovy approval last with Cigna?

Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months.

What does Cigna require to renew Wegovy?

Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Continuation requires: patient has completed ≥ 1 year of therapy; prescriber attests no worsening of fibrosis or MASH/NASH; no cirrhosis (F4); metabolic risk factors managed per standard of care; alcohol limits maintained; diet and exercise ongoing; specialist prescribing/consultation. Fibrosis staging documentation NOT re-required at continuation. ELF score, biopsy, VCTE, or MRE documentation NOT re-required at continuation.

How current is this information?

The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Cigna coverage for Wegovy (Liver Disease (MASH))

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial Approval - MASH/NASH with F2-F3 Fibrosis

All of:

Patient is ≥ 18 years of age
Patient does not have cirrhosis (F4)
Patient has stage F2 or F3 fibrosis confirmed by an accepted diagnostic test prior to initiating treatment [documentation required]
Patient has one or more metabolic risk factors managed per standard of care (central obesity, hypertriglyceridemia, reduced HDL-C, hypertension, or elevated fasting plasma glucose/diabetes/pre-diabetes)
Medication will be used in combination with appropriate diet and exercise therapy
Medication prescribed by or in consultation with an endocrinologist, gastroenterologist, or hepatologist

Plus any one of:

Liver biopsy within 3 years preceding treatment showing F2 or F3 fibrosis [documentation required]
VCTE within 6 months preceding treatment showing F2 or F3 fibrosis [documentation required]
MRE within 6 months preceding treatment showing F2 or F3 fibrosis [documentation required]
ELF test within 6 months preceding treatment with score ≥ 9.2 to ≤ 10.5 [documentation required]

Initial Approval - MASH/NASH Alcohol Limit (Female)

All of:

Female patient: alcohol consumption < 20 grams/day

Initial Approval - MASH/NASH Alcohol Limit (Male)

All of:

Male patient: alcohol consumption < 30 grams/day

Continuation - MASH/NASH (Year 2+)

All of:

Patient has completed ≥ 1 year of therapy with Wegovy injection, Wegovy HD injection, and/or Wegovy tablet
Prescriber attests patient has not had worsening of fibrosis or MASH/NASH
Prescriber attests patient does not have cirrhosis (F4)
Prescriber attests metabolic risk factors are managed per standard of care
Medication will be used in combination with appropriate diet and exercise therapy
Medication prescribed by or in consultation with an endocrinologist, gastroenterologist, or hepatologist

Plus any one of:

Female patient: alcohol consumption < 20 grams/day
Male patient: alcohol consumption < 30 grams/day

Documentation to bring

Documentation of stage F2 or F3 fibrosis prior to treatment initiation [documentation required]
Liver biopsy report within 3 years preceding treatment (if biopsy used for staging) [documentation required]
VCTE results within 6 months preceding treatment (if VCTE used for staging) [documentation required]
MRE results within 6 months preceding treatment (if MRE used for staging) [documentation required]
ELF test result within 6 months preceding treatment with score ≥ 9.2 to ≤ 10.5 (if ELF used for staging) [documentation required]
Prescriber attestation of one or more metabolic risk factors managed per standard of care
Prescriber attestation of alcohol consumption limits (female < 20 g/day; male < 30 g/day)
Documentation that medication is prescribed by or in consultation with endocrinologist, gastroenterologist, or hepatologist
Confirmation patient does not have cirrhosis (F4)

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
Renewal: Continuation requires: patient has completed ≥ 1 year of therapy; prescriber attests no worsening of fibrosis or MASH/NASH; no cirrhosis (F4); metabolic risk factors managed per standard of care; alcohol limits maintained; diet and exercise ongoing; specialist prescribing/consultation. Fibrosis staging documentation NOT re-required at continuation. ELF score, biopsy, VCTE, or MRE documentation NOT re-required at continuation.

Not covered when

Cirrhotic (F4) MASH is excluded
Alcohol consumption ≥ 20 g/day (female) or ≥ 30 g/day (male) is excluded
Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists is not covered

Policy note: Applies to both Wegovy injection (including Wegovy HD injection) and Wegovy tablet. Specialist prescribing or consultation required (endocrinologist, gastroenterologist, or hepatologist). Documentation is required as noted throughout criteria. ELF score range of 9.2 to 10.5 is specifically required (not just ≥ 9.2). For continuation, fibrosis documentation is NOT re-required; prescriber attestation of no worsening is sufficient. Rezdiffra (resmetirom) is referenced as an alternative MASH treatment in the fibrosis staging lookback criteria.

Policy effective April 15, 2026 · verified June 2, 2026 · source: Cigna — GLP-1 coverage criteria (Policy 684) · View policy document (PDF)

Does Cigna cover Wegovy for Liver Disease (MASH)?

Policy document

Applies to Employer and ACA Marketplace plans.

Qualification pathways

Documentation to bring

Approval and renewal

Not covered when